Citing 3 industry bankers, dealReporter is saying that If Allergan AGN were looking for a defensive deal, Jazz Pharmaceuticals JAZZ would likely be most viable target.
Shares of JAZZ, which have been the subject of much speculation lately, are getting a big lift on the news, trading higher by nearly 7 percent at 168. AGN is also higher by 0.78 percent at 166.80.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in